Your browser doesn't support javascript.
loading
Dengue Antiviral Development: A Continuing Journey.
Low, Jenny G; Gatsinga, Rene; Vasudevan, Subhash G; Sampath, Aruna.
Afiliación
  • Low JG; Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore.
  • Gatsinga R; Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • Vasudevan SG; Emerging Infectious Diseases Program, Duke-NUS Medical School Singapore, Singapore, Singapore.
  • Sampath A; Emerging Infectious Diseases Program, Duke-NUS Medical School Singapore, Singapore, Singapore.
Adv Exp Med Biol ; 1062: 319-332, 2018.
Article en En | MEDLINE | ID: mdl-29845542
Dengue fever is a leading cause of illness and mortality in the tropics and subtropics. There are no therapeutics currently available and a recently approved vaccine is not very efficacious demanding an urgent need to develop an effective antiviral. The path to successful dengue drug development depends on availability of relevant preclinical testing models and better understanding of dengue pathogenesis. In recent years, efforts to develop dengue therapeutics have focused on both repurposing approved drugs as well as discovery of new chemical entities that act via virus or host targeted mechanisms. Here, we discuss the various innovative approaches, their outcome, and the lessons gleaned from the development efforts.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Dengue / Virus del Dengue / Descubrimiento de Drogas Límite: Animals / Humans Idioma: En Revista: Adv Exp Med Biol Año: 2018 Tipo del documento: Article País de afiliación: Singapur

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Antivirales / Dengue / Virus del Dengue / Descubrimiento de Drogas Límite: Animals / Humans Idioma: En Revista: Adv Exp Med Biol Año: 2018 Tipo del documento: Article País de afiliación: Singapur